Takeda and Baxter formed a collaboration in August 2010 to commercialize cell culture based flu vaccines in Baxter's Vero cell system. Today, Takeda announced it has received a $313 million grant from the Japanese government to build a new flu plant in Hikari that is slated to be operational in 2013.
Takeda is looking to supply the flu vaccine to the Japanese public as soon as possible thereafter. In the medium to long term, the Company says it continue to develop vaccines for unmet medical need with a high social demand. These will include combinaton vaccines, high value vaccines using new technology and supply to other Asian and emerging markets outside of Japan.
This is another example of the rebirth of the vaccine industry after decades of slow decline as more and more governments put emphasis back on creating new vaccines to prevent widespread disease.
Posted by Bruce Lehr Aug 23rd 2011.